[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336561-105":59,"doc-detail-336561-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cd98-heavy-chain-protein-is-overexpressed-in-non-small-cell-lung-cancer-and-is-a-potential-target-for-car-t-cell-therapy","CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy","","CAR T cells show strong efficacy in hematological malignancies but remain less effective for solid tumors such as non-small cell lung cancer (NSCLC). The limited number of NSCLC-specific surface targets motivates new candidates. This work reports that CD98 heavy chain (hc) protein is overexpressed on NSCLC cells, identified using an mAb screening of over 10,000 clones. An R8H283-derived CAR T product binds NSCLC cells in patients and demonstrates significant anti-tumor activity in vivo, with future off-tumor testing required.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cd98-heavy-chain-protein-is-overexpressed-in-non-small-cell-lung-cancer-and-is-a-potential-target-for-car-t-cell-therapy/336561/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cd98-heavy-chain-protein-is-overexpressed-in-non-small-cell-lung-cancer-and-is-a-potential-target-for-car-t-cell-therapy/336561.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are CAR T cells less effective against NSCLC than hematological cancers?","Question",{"text":113,"@type":114},"Fewer NSCLC-specific cell surface targets have been identified, which limits CAR T recognition of tumor cells.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What role does CD98 heavy chain (CD98hc) play in this study?",{"text":118,"@type":114},"CD98hc is reported to be overexpressed on the surface of NSCLC cells and serves as a potential target for CAR T therapy.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the researchers assess CAR T anti-tumor effects?",{"text":122,"@type":114},"They evaluated R8H283-derived CAR T cells for specific reaction with NSCLC cells in patients and for significant anti-tumor effects in a xenograft NSCLC model in vivo.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336561,1790198376,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCD98 heavy chain protein is overexpressed in non‑small cell lung cancer and is a potential target for CART‑cell therapy  \nMotoYaga1,2, Kana Hasegawa 3, Shunya Ikeda4, Miwa Matsubara4, Takashi Hiroshima 5, Toru Kimura 5, Yuya Shirai1,6, WibowoTansri1, Hirofumi Uehara4, Mana Tachikawa4, Yuzuru Okairi7, Masayuki Sone7, Hiromi Mori7, Yosuke Kogue7, Hiroki Akamine7, Daisuke Okuzaki8,9, Kotaro Kawagishi10, Satoshi Kawanaka10, Hiroyuki Yamato10, Yukiyasu Takeuchi10, Eiji Okura11, Ryu Kanzaki12, Jiro Okami12, Itsuko Nakamichi13, Shigeru Nakane14, Aki Kobayashi15, Takashi Iwazawa15, Toshiteru Tokunaga16, Hideoki Yokouchi17, Yukihiro Yano18, Junji Uchida18, Masahide Mori18, Kiyoshi Komuta19, Tetsuro Tachi20, Hideki Kuroda20, Noriyuki Kijima20, Haruhiko Kishima20,  \nMichiko Ichii21, Shinji Futami1, Yujiro Naito1, Takayuki Shiroyama1, Kotaro Miyake1, Shohei Koyama1,22,23, Haruhiko Hirata1, Yoshito Takeda1, Soichiro Funaki 5, Yasushi Shintani5, Atsushi Kumanogoh1,2,24,25,26,27 & Naoki Hosen3,21,28*  \nChimeric antigen receptor (CAR) T cells are effective against hematological cancers, but are less effective against solid tumors such as non‑small cell lung cancer (NSCLC) . One of the reasons is that only a few cell surface targets specific for NSCLC cells have been identified. Here, we report that CD98 heavy chain (hc) protein is overexpressed on the surface of NSCLC cells and is a potential target for CART cells against NSCLC. Screening of over 10,000 mAb clones raised against NSCLC cell lines showed that mAb H2A011 bound to NSCLC cells but not normal lung epithelial cells. H2A011 recognized CD98hc. Although CART cells derived from H2A011 could not be established presumably due to the high level of H2A011 reactivity in activated T cells, those derived from the anti‑CD98hc mAb R8H283, which had been shown to lack reactivity with CD98hc glycoforms expressed on normal hematopoietic cells and some normal tissues, were successfully developed. R8H283 specifically reacted with NSCLC cells in six of 15 patients. R8H283‑derived CART cells exerted significant anti‑ tumor effects in a xenograft NSCLC model in vivo. These results suggest that R8H283 CART cells may become a new therapeutic tool for NSCLC, although careful testing for off‑tumor reactivity should be performed in the future.  \n1Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. 2Laboratory of Immunopathology, World Premier International Research Center Initiative (WPI), Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka, Japan. 3Laboratory of Cellular Immunotherapy, World Premier International Research Center Initiative (WPI), Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka, Japan. 4Department of Clinical Laboratory and Biomedical Sciences, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. 5Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. 6Department of Statistical Genetics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. 7Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan. 8Genome Information Research Center, Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Osaka, Japan. 9Laboratory of Human Immunology (Single Cell Genomics), World Premier International Research Center Initiative (WPI), Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka, Japan. 10Department of General Thoracic Surgery, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan. 11Department of Surgery, Takarazuka City Hospital, Takarazuka, Hyogo, Japan. 12Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Osaka, Japan. 13Department of Pathology, Minoh City Hospital, Minoh, Osa","cbCaisookrxT5tGw","https://ap.wps.com/l/cbCaisookrxT5tGw","pdf",4936174,"English","# Background\n# Target identification: CD98hc on NSCLC cells\n# mAb screening and CAR T development\n# Patient binding and in vivo anti-tumor effects\n# Implications and future safety testing","[{\"question\":\"Why are CAR T cells less effective against NSCLC than hematological cancers?\",\"answer\":\"Fewer NSCLC-specific cell surface targets have been identified, which limits CAR T recognition of tumor cells.\"},{\"question\":\"What role does CD98 heavy chain (CD98hc) play in this study?\",\"answer\":\"CD98hc is reported to be overexpressed on the surface of NSCLC cells and serves as a potential target for CAR T therapy.\"},{\"question\":\"How did the researchers assess CAR T anti-tumor effects?\",\"answer\":\"They evaluated R8H283-derived CAR T cells for specific reaction with NSCLC cells in patients and for significant anti-tumor effects in a xenograft NSCLC model in vivo.\"}]","CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy | PDF",1790015614,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6481831a0467a35b4d37885bd48b751.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2c250171360d6a1ad7fe4ea298c3c27.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2771d63738966c0f8108a43f1ee8278a.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4485f88f4d5600e782e1674cebcc4bdb.webp",980,1287]